Yu-ting Sun - Publications

APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways.

Journal: International immunopharmacology

Published: May 07, 2024

Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: March 18, 2024

The optimal threshold of PD-L1 combined positive score to predict the benefit of PD-1 antibody plus chemotherapy for patients with HER2-negative gastric adenocarcinoma: a meta-analysis.

Journal: Cancer immunology, immunotherapy : CII

Published: February 26, 2024

The relationship between brain metastasis and HER2 expression status in gastric cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 26, 2023

Whole-Exome Sequencing Among Chinese Patients With Hereditary Diffuse Gastric Cancer.

Journal: JAMA network open

Published: December 09, 2022

Precise microdissection of gastric mixed adeno-neuroendocrine carcinoma dissects its genomic landscape and evolutionary clonal origins.

Journal: Cell reports

Published: September 22, 2022

Novel prognostic model predicts overall survival in colon cancer based on RNA splicing regulation gene expression.

Journal: Cancer science

Published: February 04, 2022

Efficacy and safety of PD-1 inhibitors combined with chemotherapy as first-line therapy for advanced esophageal cancer: A systematic review and network meta-analysis.

Journal: International immunopharmacology

Published: January 04, 2022

High AKAP8L expression predicts poor prognosis in esophageal squamous cell carcinoma.

Journal: Cancer cell international

Published: November 29, 2021

Comparison of PD-1 Inhibitors in Patients With Advanced Esophageal Squamous Cell Carcinoma in the Second-Line Setting.

Journal: Frontiers in oncology

Published: June 10, 2021

PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial.

Journal: American journal of cancer research

Published: May 26, 2021

The Impact of Mismatch Repair Status on Prognosis of Patients With Gastric Cancer: A Multicenter Analysis.

Journal: Frontiers in oncology

Published: May 21, 2021